Ischemia-modified albumin in children with clinically suspected acute myocarditis: diagnostic performance and incremental value beyond conventional biomarkers - Takeaways - MDSpire

Ischemia-modified albumin in children with clinically suspected acute myocarditis: diagnostic performance and incremental value beyond conventional biomarkers

  • By

  • Ceren Yapar Gümüş

  • Emine Yurdakul Ertürk

  • Yeliz Kaşko Arıcı

  • Ecem İpek Altınok

  • Tülin Bayrak

  • Ahmet Bayrak

  • Taner Kasar

  • June 15, 2026

  • 0 min

Share

  • 1

    Ischemia-modified albumin (IMA) levels were significantly higher in children with suspected acute myocarditis compared to healthy controls.

  • 2

    The standalone diagnostic performance of IMA was modest, with an AUC of 0.64, indicating limited utility as a primary biomarker.

  • 3

    Conventional biomarkers like troponin I and NT-proBNP demonstrated stronger diagnostic discrimination than IMA in suspected myocarditis cases.

  • 4

    Adding IMA to a base model of conventional biomarkers marginally improved diagnostic performance, suggesting minimal added value.

  • 5

    IMA may serve as an adjunctive biomarker in pediatric acute myocarditis but is not recommended as a primary diagnostic tool.

Original Source(s)

Ischemia-modified albumin in children with clinically suspected acute myocarditis: diagnostic performance and incremental value beyond conventional biomarkers

  • by Ceren Yapar Gümüş, Emine Yurdakul Ertürk, Yeliz Kaşko Arıcı, Ecem İpek Altınok, Tülin Bayrak, Ahmet Bayrak, Taner Kasar

  • June 15, 2026

Related Content

Adoption of a Pediatric Acute Care Cardiology Inpatient Model

Exercise modalities and dose-response for LVEF Improvement in heart failure patients: a systematic review and network meta-analysis

Clinical correlation between platelet parameters and coronary artery lesions in pediatric Kawasaki disease